A study to assess the efficacy and safety of sofosbuvir and daclatasvir in HIV/HCV co-infected patients with advanced fibrosis.

Trial Profile

A study to assess the efficacy and safety of sofosbuvir and daclatasvir in HIV/HCV co-infected patients with advanced fibrosis.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2015

At a glance

  • Drugs Daclatasvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Aug 2015 Status changed from completed to recruiting as per both the results i.e presented at the meeting "50th Annual Meeting of the European Association for the Study of the Liver" and "22nd Conference on Retroviruses and Opportunistic Infections" are interim and final results with primary efficacy endpoints will be presented in future.
    • 10 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top